In a report released yesterday, Geulah Livshits from Chardan Capital reiterated a Buy rating on Replimune Group Inc (REPL), with a price target of $28. The company’s shares closed last Monday at $10.05, close to its 52-week low of $8.88.
“We expect the 4Q19 data from the phase I portion, potentially at the Cancer (SITC) annual meeting in November, will focus on safety and early signals of immune activity of RP1 as a single agent and in the combo setting. Per management, the company plans to accumulate data from the phase II cohorts over the next ~6 months and begin reporting on a per cohort basis over 2020 (consistent with prior timelines). RP1 trial, a registration-directed randomized controlled study in cutaneous squamous cell carcinoma (CSCC) +/- Regeneron’s (unrated) anti-PD1 cemiplimab is expected to begin in August. Replimune ended the quarter with $120.8 mm in cash, cash equivalents and short-term investments. This provides the company with a cash runway into calendar year 2H21.”
According to TipRanks.com, Livshits is a 3-star analyst with an average return of 7.2% and a 56.0% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Logicbio Therapeutics Inc, and Crispr Therapeutics AG.
Currently, the analyst consensus on Replimune Group Inc is a Strong Buy with an average price target of $26.67.
See today’s analyst top recommended stocks >>
Based on Replimune Group Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $9.51 million. In comparison, last year the company had a GAAP net loss of $10.04 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Oncolytic immunotherapy is a cancer treatment that exploits the ability of certain viruses to selectively replicate in an direct kill turmors, as well as induce a potent, patient-specific, anti-tumor immune response. The company was founded by Philip Astley-Sparke, Colin Love and Robert Coffin in March 2015 and is headquartered in Woburn, MA.